In Section C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will receive ABBV-744 and ruxolitinib. Participants will acquire treatment right up until disorder progression or maybe the contributors are unable to tolerate the study drugs. There might be bigger treatment stress for contributors Within this trial https://abbv-744cancertreatmentcl02457.blogdiloz.com/31158728/the-fact-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-that-no-one-is-suggesting